RAG-21

N/A

Report date: 2025/08/07 20:00:08
NME

Base Information

Drug NameRAG-21
Drug Alias NameRAG-21
ClassificationSmall molecules > Nucleosides and nucleotide derivtives > Oligonucleotide > Small Interfering RNA
Mechanisms of ActionRNA-binding protein FUS modulators
TargetsRNA-binding protein FUS
Therapy Area/IndicationsAmyotrophic Lateral Sclerosis
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesRactigen Therapeutics (Nantong) Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesRactigen Therapeutics (Nantong) Co LtdBeijing Tiantan Hospital, Capital Medical University
Inactive CompaniesN/A
Active IndicationsAmyotrophic Lateral Sclerosis
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A